Clinical Trials Arena on MSN

AstraZeneca’s COPD drug gains third Phase III win

Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and ...
Hosted on MSN

AstraZeneca’s novel COPD drug secures double win in Phase III

AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the drug to capture a ...
Fierce Pharma

AZ's Breztri nabs FDA asthma nod, adding fuel to blockbuster launch

After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has ...
Medscape

Costs of Drugs Can Be Breathtaking for COPD Patients

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
KSHB Kansas City

FDA approves first Symbicort generic drug for asthma and COPD

The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
AOL

FDA approves new COPD drug developed by firm in Raleigh. First new treatment in a decade

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
Monthly Prescribing Reference

TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts

So far, TrumpRx lists fewer than 60 drugs, mostly brand-name medicines. Many already have cheaper generic versions. HealthDay News — TrumpRx, the president’s discount program for prescription drugs, ...